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Background: Migraine is a common neurovascular disorder with symptoms including headache of moderate to
severe intensity and recurring attacks. There is no cure for migraine today and the pathology is poorly understood.
Common forms of migraine have a complex genetic background and heritability has been estimated to be around
50%. Recent genome-wide association studies (GWAS) on European and American migraine cohorts have led to the
identification of new genetic risk factors for migraine.
Methods: We performed an association study in a Swedish population based cohort, investigating the frequency of
eight single nucleotide polymorphisms (SNPs) recently identified as genetic risk factors for migraine in three GWAS,
using available array data (Illumina Omni Express chip). The eight SNPs were rs2651899, rs3790455, rs10166942,
rs7640543, rs9349379, rs1835740, rs6478241 and rs11172113. Because information on rs3790455, rs10166942 and
rs7640543 was not directly available, we selected SNPs in high Linkage Disequilibrium (LD) with these three SNPs,
and replaced them with rs2274316, rs1003540 and rs4075749, respectively.
Results: We were able to replicate the association with rs2651899 and found a trend for association with rs1835740
in our Swedish cohort.
Conclusions: This is the first reported genetic association study of a Swedish migraine case control material. We
have thus replicated findings of susceptibility loci for migraine in an independent genetic material, thereby increasing
knowledge about genetic risk factors for this common neurological disorder.
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Migraine is a common neurovascular disorder with a
strong genetic component. Symptoms include headache
of moderate to severe intensity and recurring attacks.
Diagnosis is made according to the criteria of the Inter-
national Classification of Headache Disorders (ICHD-II)
from the International Headache Society (IHS) [1]. There
are two main subgroups of the disorder: migraine with
aura (MA) and migraine without aura (MO), with the
latter being the most common subtype. Aura is defined
as a period with variable focal neurological symptoms,
most commonly affecting vision and occasionally also the* Correspondence: Andrea.Carmine.Belin@ki.se
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unless otherwise stated.sensory system, that precede and sometimes accompany
the headache phase. Many patients having migraine with
aura sometimes also experience attacks without aura.
In concordance with the global lifetime prevalence of
migraine, which has been reported to be 14% [2], the life-
time prevalence of migraine in the Swedish population is
13,8% [3], which corresponds to more than one million
people. Thus, migraine is a major neurological disease of
considerable public health relevance. There is a female to
male predominance, with a peak in middle aged women
[2,4]. There also seems to be some regional differences in
prevalence with more migraine patients in Europe and
North America compared to the rest of the world [2].
Having relatives with migraine is a strong risk factor and
heritability has been estimated to be as high as 50% [5].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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The symptoms of migraine headache are commonly
hypothesized to be caused by activation of trigeminal
nerve fibers and the C2 nerve fibers that coil around
the large arteries of the brain and release of vasodilating
chemicals such as calcitonin-gene-related peptide (CGRP)
[6,7]. Activation of these nerves is assumed to cause pain
and inflammation. Sensitization of the primary afferent
nociceptive neurons innervating the vessels and the dura
mater may increase their responsiveness at the site of
inflammation [8].
An alternative hypothesis for migraine headaches is
increased brain excitability. This is supported by genetic
findings in familial hemiplegic migraine (FHM), a rare
monogenic subtype of MA, where mutations are found
in ion channels, potentially influencing cellular excit-
ability [9,10]. This is in agreement with the finding that
topiramate, a calcium channel blocker generally used to
treat epilepsy, has been shown to be effective in migraine
as well [11]. Genetic studies in the common forms of
migraine have had limited success in the past decade.
However, in three recent genome-wide association studies
(GWAS) on large European migraine cohorts, a first set of
genetic risk factors for migraine has been identified
[12-14]. In the first study by Anttila et al., the single
nucleotide polymorphism (SNP) rs1835740 was identified
as associated with migraine in a two stage GWAS in
seven North European migraine populations [12]. A strong
association with migraine was found for the minor allele of
rs1835740 on 8q22.1 (p = 5.38 × 10−9). This genetic risk
factor was stronger for MA, than MO. The SNP rs1835740
is located in a 27 kb haplotype block between two genes
involved in glutamate homeostasis, MTDH (metadherin,
astrocyte elevated gene 1) and PGCP (plasma glutamate
carboxypeptidase). Anttila et al. further performed an
expression quantitative trait locus (eQTL) analysis which
revealed that the rs1835740 risk allele was associated with
higher MTDH expression. In addition, MTDH was also
recently found to be associated with migraine in a
genome-wide meta-analysis including six population-
based European cohorts [15]. The second GWAS was
performed on a cohort consisting of more than 20,000
American women of European descent. Results were
replicated in two smaller independent samples of European
migraine patients [13]. Three associations were found;
rs2651899, rs10166942 and rs11172113, none of which
were preferential for MA or MO. Rs2651899 is located
in the gene PRDM16 (PR domain containing 16), a zinc
finger transcription factor whose potential role in migraine
is unclear. Rs10166942 is located close to the transcription
start site for TRPM8 (Transient receptor potential cation
channel, subfamily M, member 8). TRPM8 is a sensor
for cold mainly expressed in the peripheral nervous
system, and is likely to be involved in neuropathic pain[16]. Rs11172113 maps to LRP1 (Low density lipoprotein
receptor-related protein 1), an endocytotic receptor
protein involved in multiple cellular functions, such as
modulating neuronal glutamate signaling [17] and lipid
homeostasis [18], as well as being involved in the clearance
of apoptotic cells [19] and amyloid precursor protein
[20]. Findings of association with both rs10166942 and
rs11172113 were recently replicated in a Scandinavian
cohort consisting of more than 2,500 migraine patients
[21]. The third GWAS was performed on German and
Dutch migraine patients without aura, and the material
partially overlapped with the Anttila study [14]. The study
found associations with four new loci: MEF2D (myocyte
enhancer factor 2D), TGFBR2 (transforming growth factor
β receptor 2), PHACTR1 (phosphatase and actin regulator
1) and ASTN2 (astrotactin 2), and also replicated the
previously reported associations with TRMP8 and LRP1.
The SNPs with the strongest association at the respective
locus were: rs3790455 (MEF2D), rs7640543 (TGFBR2),
rs9349379 (PHACTR1), and rs6478241 (ASTN2). MEF2D
is a transcription factor that promotes the survival of
newly formed neurons in the brain [22]. MEF2D also
influences the number of excitatory synapses in an activity
dependent manner, and might thus influence neuronal
excitability, which is an appealing role for a migraine
candidate gene. PHACTR1 regulates the activity of PP1
(protein phosphatase 1), which is known to influence
synaptic activity and morphology [23,24]. TGFBR2 is a
serine-threonine kinase involved in proliferation, and
ASTN2 codes for a protein expected to influence neuronal
migration [25,26].
Due to previous findings of mutations in ion channels
causing different forms of FHM, genetic studies of migraine
have up until recently mainly been limited to these areas
of the genome. However, recent advancements in high-
throughput genotyping technology have enabled more
hypothesis free searches of the whole genome, revealing
new susceptibility loci for migraine. Findings from these
GWAS should be replicated in independent populations,
since genetic risk- or protective factors can vary between
different populations. Therefore the aim of the present
study was to perform a replication study in a Swedish
cohort on eight SNPs identified as genetic risk factors
for migraine in large European and American GWAS.
Material
The genetic material, consisting of 9,897 Swedish individ-
uals, was collected by the Swedish Twin Registry. We
declare that all experiments on human subjects, human
material and human data have been performed in accord-
ance with the Declaration of Helsinki. All procedures were
carried out with the adequate understanding and written
consent of the subjects. Formal approval to conduct the
experiments described has been obtained from the human
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number 2007/644-31). The occurrence of migraine was
self-assessed through a questionnaire using the criteria
for migraine of the ICHD-II [1]. Participants were asked
to address the following questions to be answered “yes”,
“no” “do not know”, or “don’t want to answer”: 1) recur-
rent headache not related to infection, fever or alcohol
consumption (past or present); 2) headache attacks some-
where between 4 hours and 3-days if no medication
against the pain is taken; 3) at least two out of four pain
features (moderate or severe intensity, one-sided location,
pounding/throbbing quality, and aggravation by routine
physical activity; and 4) at least one out of two accompany-
ing symptoms (nausea and/or vomiting, and increased
sensitivity to light and sound) [5]. Information on migraine
with aura could be retrieved from follow-up questions also
answered by “never”, “sometimes”, “always”, “don’t know”,
or “don’t want to answer”: Do you usually just before
the headache begins have any of the following symptoms:
visual disturbances, blurred vision, see flashes, flickering
or zigzag lines, have difficulty reading or loss of letters.
These symptoms must persist for at least 5 minutes and
maximum 1 hour.
Methods
The material includes both patients with and without
aura, but for most subjects, information on aura is missing
and the two groups were therefore not analyzed separately
in our study. 910 individuals were classified as having
migraine according to ICHD-II and 7,544 were not. The
remaining 1,443 individuals, for whom this information
was not available, were not included in this study. Geno-
typing was done on the Illumina Omni Express chip at
the SNP&SEQ Technology Platform, Uppsala University.
After an initial quality control performed by the platform
core facility, controlling for missingness (max 0.03 geno-
types missing per-SNP), low genotyping rate (max 0.03
genotypes missing per-individual), SNP frequency (minor
allele frequency < 0.01), genetic sex, Hardy Weinberg equi-
librium (p ≤ 1e−07) and heterozygosity, data from 644,556
single nucleotide polymorphisms (SNP) remained.
We performed cryptic as well as subject relatedness
analyses, making sure there were no unknown relations
in the material, which resulted in the removal of 137
subjects. In order to perform an association analysis we
selected one twin from each pair, keeping the twin with
migraine when diagnosis was discordant. From concord-
ant pairs, one twin was randomly selected. A population
stratification analysis based on MDS (minimum distance
separation) calculations in four dimensions revealed one
outlier, which was also removed (defined as deviating
more than 6 standard deviations from the mean), leaving
749 cases (78% females) and 4,018 controls (47% fe-
males). After quality control we performed a one-degreeof freedom allelic chi-square (χ2) test and calculated the
genomic inflation factor λ to 1.005.
Three of the selected SNPs, rs3790455, rs10166942,
and rs7640543, had not been genotyped in our material,
why we instead included other genotyped SNPs, rs2274316,
rs1003540, and rs4075749 respectively, in high linkage
disequilibrium (r2 > 0.89) with the initially selected ones
(Table 1). Thus genotyping data for rs2651899, rs2274316,
rs1003540, rs4075749, rs9349379, rs1835740, rs6478241,
and rs11172113 were extracted for all 749 cases and 4,018
healthy controls. Power analysis revealed that, with our
sample size we should be able to detect effect sizes with
odds ratios <0.753 and >1.294 with a minor allele frequency
(MAF) of 0.22 in controls (power = 80% and α = 0.05). For
the association test we performed a logistic regression
analysis using gender as cofactor to eliminate any bias
introduced by the predominance of female migraine
patients in our material.
To evaluate the distribution of carrying more than one
risk allele between cases and controls, an unweighted
cumulative risk analysis for our eight selected SNPs was
performed. Risk alleles were defined using odds ratios
published in a previous study (Table 1) [14]. For two of
the substituted SNPs (rs1003540 and rs4075749) we
used HapMap Genome Browser (Phase 1, 2 and 3
merged genotypes and frequencies, build 37) at the Inter-
national Haplotype Mapping Project web site (www.hap-
map.org) to determine which proxy allele lies on the same
haplotype as the published risk allele. Possible differences
between control subjects and migraine patients were eval-
uated using a Chi-square test for trend.
Analyses were performed using PLINK v1.07 [27], Graph-
Pad Prism version 5.03, (GraphPad Software, San Diego
California USA), power and sample size software (PS
version 3.0 http://biostat.mc.vanderbilt.edu/wiki/Main/
PowerSampleSize) and R version 2.15.2, a free software
programming language for statistical analyses [28].
Results
We studied eight SNPs previously identified as genetic
risk factors for migraine in European GWAS: rs2651899
(1p36.32), rs3790455 (1q22), rs10166942 (2q37.1), rs7640
543 (3p24), rs9349379 (6p24), rs1835740 (8q22), rs6478241
(9p33) and rs11172113 (12q13.3) [12-14]. Because infor-
mation on rs3790455, rs10166942 and rs7640543 was not
available from the Illumina Omni Express chip data, we
replaced them with genotyped markers in high linkage
disequilibrium (r2 > 0.89). The replacement markers were
rs2274316, rs1003540, and rs4075749 respectively, see
Table 1. The disease-association test was performed with a
logistic regression analysis using gender as a cofactor, with
Bonferroni correction for multiple testing.
Allele frequencies and association results for all SNPs
are shown in Table 2. We found that one of the SNPs
Table 1 Eight SNPs analyzed for association with migraine in a Swedish population-based cohort
Chr SNP of interest Alleles Replacement SNP Gene Alleles Risk Allele MAF OR
1 rs2651899 T > C PRMD16 C 0.45 1.10
1 rs3790455 rs2274316 MEF2D A > C C 0.34 1.23
2 rs10166942 rs1003540 TRMP8 A > G A Na Na
3 rs7640543 rs4075749 TGFBR2 T > C C Na Na
6 rs9349379 A > G PHACTR1 A 0.38 0.82
8 rs1835740 C > T MTDH T 0.22 1.0
9 rs6478241 G > A ASTN2 A 0.38 1.22
12 rs11172113 T > C LRP1 T 0.4 0.86
Chr = chromosome; SNP of interest = SNPs identified in previous GWAS, see article text for references; Replacement SNP = SNPs of interest not genotyped on the Illumina
chip were replaced with other genotyped SNPs in linkage disequilibrium with the SNP of interest (r2 > 0.89); Gene = the SNPs are either located within or close to these
genes; MAF = minor allele frequency from Freilinger et al. [14]; OR = odds ratio from Freilinger et al. [14].
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graine in Europe by Chasman et al. [13], was associated
with migraine also in Sweden. The minor allele of
rs2651899 was more common in cases than in controls,
the association was significant before (p = 0.0019) and
after Bonferroni correction (pc = 0.0150). This association
gave an odds ratio of 1.20 with a 95% confidence inter-
val (CI) of 1.07-1.35 indicating that the minor allele
confers an increased risk of migraine. We also found a
trend for association with the minor allele of rs1835740
and migraine (p = 0.0075, pc = 0.0600) with an odds ratio
of 1.28, 95% CI of 1.07-1.54. The six remaining SNPs
showed no statistically significant association with mi-
graine in our material. All eight SNPs were in Hardy
Weinberg equilibrium in control individuals (data not
shown). A formal interaction test to investigate if the
eight SNPs would have different effects in males and fe-
males showed no significant association (Table 3).
In order to evaluate the distribution of risk alleles be-
tween migraine patients and controls, we performed an
unweighted cumulative risk analysis for our eight selected
SNPs. Most individuals had between five and nine risk
alleles (82% of the controls and 80% of the patients).
Subjects were divided into eight bins depending onTable 2 Association results for the eight SNPs included in the









The disease-association test was performed using logistic regression analysis with gend
frequency; corrected p-value was calculated using the Bonferroni correction method; O
shown in bold (p < 0.05).their number of risk alleles (Table 4). The two bins with
the lowest number of alleles (0–1 and 2–3) as well as
the two bins with the highest number of alleles (12–13
and 14–16) were merged in the analysis in order to avoid
bins containing zero individuals. Differences between con-
trol subjects and migraine patients were then evaluated
using a (χ2) test for trend. Figure 1 shows that the control
group had higher percentages of individuals carrying lower
risk allele loads, whereas the migraine group generally had
greater percentages of individuals carrying higher risk al-
lele loads. The overall difference when comparing controls
to migraine patients was significant with a (χ2) test for
trend of 16.31 and a p-value < 0.0001.
Discussion
We have performed an association study in a Swedish
material on eight SNPs previously identified as genetic
markers for migraine. This is the first reported genetic
association study done in a Swedish migraine case control
material. It is well known that women are more likely to
develop migraine than men, and in our material 78% of
the patients were women. We therefore performed the
disease-association test by using a logistic regression ana-
lysis controlling for gender. We were able to replicate theanalysis
p-value Corrected p-value OR (95% CI)
0.0019 0.0150 1.20 (1.07-1.35)
0.6143 1 0.97 (0.85-1.11)
0.0692 0.5538 0.81 (0.64-1.02)
0.3961 1 1.06 (0.93-1.21)
0.4957 1 0.96 (0.85-1.08)
0.0075 0.0600 1.28 (1.07-1.54)
0.6192 1 1.03 (0.91-1.17)
0.1569 1 0.92 (0.82-1.03)
er as cofactor. SNP = Single Nucleotide Polymorphism; MAF = minor allele
R = odds ratio; 95% CI = 95% confidence interval. The significant p values are
Table 3 Allele frequencies in males and females separately
Females (n = 2471, nM = 587) Males (n = 2296, nM = 162)
SNP ID MAF cases MAF controls MAF cases MAF controls Formal interaction test p-value
rs2651899 0.4608 0.4095 0.4189 0.3942 0.4574
rs2274316 0.3646 0.3590 0.3426 0.3522 0.6326
rs1003540 0.1857 0.2123 0.1574 0.2022 0.4606
rs4075749 0.3311 0.3138 0.3272 0.3123 0.9317
rs9349379 0.4370 0.4429 0.4228 0.4353 0.8449
rs1835740 0.2129 0.1948 0.2037 0.2031 0.5064
rs6478241 0.3739 0.3718 0.3827 0.3515 0.3549
rs11172113 0.3978 0.4094 0.3457 0.4189 0.059
n = number of individuals; nM = number of Migraineurs; SNP = Single Nucleotide Polymorphism; MAF = Minor allele frequency; Formal interaction test of the logistic
regression performed with gender as covariate.
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Moreover, we see a trend for association for rs1835740
with migraine. Our analyses indicate that the association
of rs2651899 and the trend for association of rs1835740
was not confounded by the female predominance in this
cohort. In addition we found that migraine patients overall
were more likely to carry the previously identified risk
alleles than the control subjects.
Rs2651899 was first reported by Chasman et al. [13] in
a population-based cohort including migraine patients
both with and without aura, which is in agreement
with the background of the cohort used in our study.
Rs2651899 has also been confirmed to be a risk factor
for migraine in a meta-analysis including both clinical-
and population-based cohorts [21] and in MO patients
in a Chinese cohort [29]. The minor allele of this SNP was
associated with an increased risk of migraine also in our
Swedish cohort. The rs2651899 variant has in contrast to
these results recently been reported to have a protective
effect on migraine susceptibility in a North Indian popu-
lation [30]. The allele frequencies that we report for
this SNP (0.4014%), is consistent with that reported for
Europeans by Hap Map. However, allele frequencies
seem to vary slightly between populations and the
minor allele, C, which is also the ancestral allele, isTable 4 Distribution of risk alleles among controls and
migraine patients
Number of Alleles Control % (n) Migraine % (n)
0-1 0 (2) 0
2-3 2.0 (82) 1.5 (11)
4-5 16.4 (660) 14.4 (108)
6-7 39.1 (1573) 35.1 (263)
8-9 32.2 (1293) 33.6 (252)
10-11 9.1 (366) 13.9 (104)
12-13 1.0 (42) 1.3 (10)
14-16 0 0.1 (1)
n = number of individuals.found to be more common in some populations of African
and Asian descent. The divergence of results observed
here between a Swedish and an Indian cohort, might
simply reflect a different genetic background. Genetic risk
factors of migraine may also vary between populations,
which is supported by the differences in prevalence de-
scribed previously [2].
Rs1835740 was first reported as a risk factor for mi-
graine by Anttila et al. [12] in a GWAS on seven European
migraine case control materials from specialized headache
clinics. The cases were divided into subgroups based on a
diagnosis of MA or MO, and the effect of rs1835740 was
stronger in individuals with MA. The North Indian study
also reported significance for the heterozygous rs1835740
genotype in migraine patients (MO and MA) and more
strongly so in MO [30]. Depending on the cohort back-
ground, different severity forms of the disorder may be
represented, and therefore the underlying combination of
genetic risk factors could also differ. Moreover, it has been
suggested that the different phenotypes of migraine (e.g.
with and without aura) represent different subgroups of
the disorder with different genetic risk alleles involved inFigure 1 Results from the unweighted cumulative risk analysis.
Differences in binned distributions of risk alleles for unweighted analysis
were significant with a chi-square (Χ2) of 16.31 and a p-value < 0.0001.
No = number.
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esting that this SNP also show a trend for association in
the Swedish material, which is a population-based cohort
including migraine patients both with and without aura.
Note that the OR of 1.28 supports the hypothesis of the
minor allele of rs1835740 conferring an increased risk
of migraine. This OR is of a magnitude usually seen for
common genetic variations in common disorders, and
the 95% CI is clearly separated from zero. Considering our
power analysis based on an OR of >1.294, this association
would likely become significant if investigated in a slightly
larger population.
Before the recently reported GWAS on migraine the
search for candidate genes mainly evolved around ion
channels. Mutations in ion channels have been shown to
lie behind different forms of FHM [10,31], and the same
genes were expected to influence all forms of migraine.
In the recently published GWAS however, new groups
of candidate genes have been proposed. PRDM16, which
harbors rs2651899, is a zink finger transcription factor
involved in the differentiation of brown adipose tissue
in addition to repression of TGF-β (Transforming growth
factor beta) signaling [32,33]. How PRDM16 might con-
tribute to migraine pathology remains to be elucidated.
Positive GWAS findings indicate genetic loci that are
associated with disease, while the true risk variant might
be another SNP in strong linkage disequilibrium with
rs2651899. Another possibility could be that rs2651899 is
linked with a copy number variant or another structural
variation causing the disease. An interesting follow up
on this marker would be to use next-generation high-
throughput sequencing technology and sequence a large
number of cases carrying this variant in order to study this
region more in detail.
Rs1835740 is located in a haplotype block between
two genes involved in glutamate homeostasis, MTDH
and PGCP. Anttila et al. performed an eQTL analysis
which revealed that the rs1835740 risk allele was associated
with higher MTDH expression [12]. MTDH has mainly
been studied regarding its involvement in carcinogenesis,
but has also been shown to downregulate SLC1A2 (Solute
carrier family 1, member 2), a major glutamate trans-
porter in the brain. Down regulation of this gene leads
to increased glutamate levels in the synaptic cleft and
SLC1A2 knockout mice have been shown to suffer from
lethal spontaneous epileptic seizures [34]. Thus, theMTDH
variant can indirectly affect the transport of glutamate at
the synapse, supporting a role for disturbed glutamate
homeostasis in migraine.
There is a clear predominance of females amongst
migraine patients, which could very well be reflected in
gender-specific risk factor differences. There is one sub-
group of female migraine patients for instance, where the
migraine attacks are initiated by hormonal fluctuations[35]. As shown by the formal interaction analysis, however,
the eight SNPs studied by us did not have significantly
different effects in females compared to males. It would
nevertheless be interesting to see larger migraine cohorts
analyzed with correction for gender and/or gender specific
strata to investigate if certain alleles are more important in
female or male patients. It is also of importance to find
out how these risk factors affect men and women differ-
ently and what pathological mechanisms are involved.
With the recent advances in genetic migraine research
we might expect to find that different forms of migraine;
for example with or without aura, associate stronger
with certain risk factors. If so, varying symptoms coupled
to specific genotypes may suggest that migraine should
rather be viewed as a spectrum of disorders than as a
single, well defined disease. Functional studies of genetic
variants associated with the disease will be necessary to
further investigate the molecular pathways of involved
genes in order to develop better treatment strategies for
migraine patients.
One limitation of our study is that the diagnosis of
migraine in our population was self-assessed based on
a questionnaire with the ICHD-II criteria for migraine
and not evaluated by a clinician. While the fact that
previously identified risk alleles were verified or implicated
in the Swedish material suggests that our questionnaire-
based identification of migraine sufferers had sufficient
discriminative power, a sharper image of genetic risk may
be obtained in the future if participants are directly inter-
viewed by neurologists.Conclusions
Our association study of a Swedish population-based co-
hort including migraine patients with and without aura,
focusing on eight previously identified risk SNPs in large
European GWAS, showed rs2651899 to be significantly as-
sociated with migraine. This strengthens previous findings
of this marker as a variant involved in migraine pathology.Competing interests
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